medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2023, Number 3

<< Back Next >>

Arch Neurocien 2023; 28 (3)

Evaluation of the antioxidant effect of olanzapine in combination with N-acetylcysteine in a mouse model of MK-801-induced schizophrenia

Lamas-Aguilar R, Pérez-Neri I, Ríos C, Mata-Bermúdez A, Martínez E, Manning N, Diaz-Ruiz A

Language: English
References: 54
Page: 7-14
PDF size: 317.01 Kb.


ABSTRACT

Introduction: Schizophrenia is a chronic condition affecting 1% of the population. One of the main theories about its etiology points out that hypofunction in N-methyl-D-aspartate (NMDA) glutamate receptors induces a loss of balance between the production of oxidative species generated in cellular metabolism and the antioxidant defense systems, which generates a state of oxidative stress. N-acetylcysteine (NAC) has been proposed as an adjuvant agent to potentiate the efficacy of atypical antipsychotics such as olanzapine (OLZ), improving the oxidative processes of the disease. Methods: Thirty mice divided into five experimental groups were administered MK-801 (an NMDA antagonist) as a model of schizophrenia. The involvement of oxidative stress was evaluated by measuring lipid peroxidation and reduced glutathione concentration at the level of the frontal cortex. Results: MK-801 administration produced increased lipid peroxidation and decreased reduced glutathione concentration at the level of the frontal cortex. Both OLZ and NAC treatments, administered alone or in combination, decreased lipid peroxidation and increased reduced glutathione in the frontal cortex. Discussion: These data suggest that OLZ and NAC treatment, given alone or in combination, regulate oxidative damage inherent to the disease and could be an option for patients with chronic psychosis or with poor response to current treatment regimens. However, further studies are required to demonstrate their efficacy and safety.


REFERENCES

  1. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, StockingsE, Scott JG, et al. Global epidemiology and burden ofschizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195-203. doi: 10.1093/schbul/sby058.

  2. Jablensky, A. Epidemiology of schizophrenia: the Global Burdenof Disease and disability. Eur Arch Psychiatry Clin Neurosci.2000;250:274-85. doi: 10.1007/s004060070002

  3. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a conciseoverview of incidence, prevalence, and mortality. Epidemiol Rev.2008;30(1):67-76. doi: 10.1093/epirev/mxn001

  4. McCutcheon RA, Marques TR, Howes OD. Schizophrenia—anoverview. JAMA Psychiatry. 2020;77(2):201-10. doi: 10.1001/jamapsychiatry.2019.3360

  5. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortalityin schizophrenia. Annu Rev Clin Psychol. 2014;10(1):425-48.doi: 10.1146/annurev-clinpsy-032813-153657

  6. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Yearsof potential life lost and life expectancy in schizophrenia: asystematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295-301. doi: 10.1016/S2215-0366(17)30078-0.

  7. Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA,Vos T. Excess mortality from mental, neurological and substanceuse disorders in the Global Burden of Disease Study 2010.Epidemiol Psychiatr Sci. abril de 2015;24(2):121-40. doi:10.1596/978-1-4648-0426-7_ch3

  8. Aquino-Miranda G, Rivera-Ramírez N, Márquez-Gómez R,Escamilla-Sánchez J, González-Pantoja R, Ramos-Languren L-E,et al. Histamine H3 receptor activation reduces the impairmentin prepulse inhibition (PPI) of the acoustic startle responseand Akt phosphorylation induced by MK-801 (dizocilpine),antagonist at N-Methyl-d-Aspartate (NMDA) receptors. ProgNeuropsychopharmacol Biol Psychiatry. 2019;94:109653. doi:10.1016/j.pnpbp.2019.109653

  9. Nakazawa K, Sapkota K. The origin of NMDA receptorhypofunction in schizophrenia. Pharmacol Ther.2020;205:107426. doi: 10.1016/j.pharmthera.2019.107426

  10. Slifstein M, van de Giessen E, Van Snellenberg J, ThompsonJL, Narendran R, Gil R, et al. Deficits in prefrontal cortical andextrastriatal dopamine release in schizophrenia: a positronemission tomographic functional magnetic resonance imagingstudy. JAMA Psychiatry. 2015;72(4):316-24. doi: 10.1001/jamapsychiatry.2014.2414

  11. Miller EK, Cohen JD. An integrative theory of prefrontal cortexfunction. Annu Rev Neurosci. 2001;24:167-202. doi: 11.1146/annurev.neuro.24.1.167

  12. Hoffman P. The meaning of ‘life’ and other abstract words: Insightsfrom neuropsychology. J Neuropsychol. 2016;10(2):317-43.doi: 10.1111/jnp.12065

  13. Wood SJ, Yücel M, Pantelis C, Berk M. Neurobiology ofschizophrenia spectrum disorders: the role of oxidative stress.2009;38(5):6.

  14. Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S.Putative neuroprotective pharmacotherapies to target thestaged progression of mental illness. Early Interv Psychiatry.2019;13(5):1032-49. doi: 10.1111/eip.12775

  15. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O’Neil A,et al. Oxidative & nitrosative stress in depression: Why so muchstress? Neurosci Biobehav Rev. 2014;45:46-62. doi: 10.1016/j.neubiorev.2014.05.007

  16. Halliwell B. Role of free radicals in the neurodegenerativediseases. Drugs Aging. 2001;18(9):685-716. doi:10.2165/00002512-200118090-00004

  17. Bavarsad Shahripour R, Harrigan MR, Alexandrov AV.N-acetylcysteine (NAC) in neurological disorders: mechanismsof action and therapeutic opportunities. Brain Behav.2014;4(2):108-22. doi: 10.1002/brb3.208

  18. Andreazza AC, Frey BN, Valvassori SS, Zanotto C, Gomes KM,Comim CM, et al. DNA damage in rats after treatment withmethylphenidate. Prog Neuropsychopharmacol Biol Psychiatry.2007;31(6):1282-8. doi: 10.1016/j.pnpbp.2007.05.012

  19. Su L-J, Zhang J-H, Gomez H, Murugan R, Hong X, Xu D, etal. Reactive oxygen species-induced lipid peroxidation inapoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev.

  20. 2019;2019:5080843. doi: 10.1155/2019/508084320. Que X, Hung M-Y, Yeang C, Gonen A, Prohaska TA, Sun X, et al.Oxidized phospholipids are proinflammatory and proatherogenicin hypercholesterolemic mice. Nature. 2018; 558(7709):301-6.doi: 10.1038/s41586-018-0198-8

  21. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: anovel treatment target in psychiatry. Trends Pharmacol Sci.2008;29(7):346-51. doi: 10.1016/j.tips.2008.05.001

  22. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predictsclinical and pharmacological potencies of antischizophrenicdrugs. Science. 1976; 192(4238):481-3. doi: 10.1126/science.3854

  23. Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics:Mechanisms underlying clinical response and side-effectsand novel treatment approaches based on pathophysiology.Neuropharmacology. 2020;172:107704. doi: 10.1016/j.neuropharm.2019.107704

  24. Vaquero-Baez M, Díaz-Ruíz A, Tristán-López L, Aviña-CervantesC, Torner C, Ramírez-Bermúdez J, et al. Clozapine anddesmethylclozapine: correlation with neutrophils and leucocytescounting in Mexican patients with schizophrenia. BMC Psychiatry.2019;19(1):295. doi: 10.1186/s12888-019-2286-1

  25. Lowe P, Krivoy A, Porffy L, Henriksdottir E, Eromona W, Shergill SS.When the drugs don’t work: treatment-resistant schizophrenia,serotonin and serendipity. Ther Adv Psychopharmacol.2018;8(1):63-70. doi: 10.1177/2045125317737003

  26. Komossa K, Rummel‐Kluge C, Hunger H, Schmid F, Schwarz S,Duggan L, et al. Olanzapine versus other atypical antipsychoticsfor schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654. doi: 10.1002/14651858

  27. Fulton B, Goa KL. Olanzapine: a review of its pharmacologicalproperties and therapeutic efficacy in the management ofschizophrenia and related psychoses. Drugs. 1997;53(2):281-98. doi: 10.2165/00003495-199753020-00007

  28. Barbosa L, Bernardo M. Utilización de olanzapina en eltratamiento de la esquizofrenia y el trastorno bipolar. PsiquiatrBiológica. 2016;23(1):4-22.

  29. Atmaca M, Kuloglu M, Ustundag B. Serum leptin and triglyceridelevels in patients on treatment with atypical antipsychotics. J ClinPsychiatry. 2003;64(5):598-604. doi: 10.4088/jcp.v64n0516

  30. Abdul-Monim Z, Reynolds GP, Neill JC. The effect of atypical andclassical antipsychotics on sub-chronic PCP-induced cognitivedeficits in a reversal-learning paradigm. Behav Brain Res.2006;169(2):263-73 doi: 10.1016/j.bbr.2006.01.019

  31. Goetghebeur P, Dias R. Comparison of haloperidol, risperidone,sertindole, and modafinil to reverse an attentional set-shiftingimpairment following subchronic PCP administration in therat—a back translational study. Psychopharmacology (Berl).2009;202(1-3):287-93. doi: 10.1007/s00213-008-1132-9

  32. Song JC, Seo MK, Park SW, Lee JG, Kim YH. Differentialeffects of olanzapine and haloperidol on MK-801-inducedmemory impairment in mice. Clin Psychopharmacol Neurosci.2016;14(3):279-85. doi: 10.9758/cpn.2016.14.3.279

  33. Liu X, Li J, Guo C, Wang H, Sun Y, Wang H, et al. Olanzapinereverses MK-801-induced cognitive deficits and region-specificalterations of NMDA receptor subunits. Front Behav Neurosci.2018;11:260. doi: 10.3389/fnbeh.2017.00260

  34. Park SW, Lee CH, Cho HY, Seo MK, Lee JG, Lee BJ, et al. Effectsof antipsychotic drugs on the expression of synaptic proteins anddendritic outgrowth in hippocampal neuronal cultures. SynapNYN. 2013;67(5):224-34. doi: 10.1002/syn.21634

  35. Reddy NR, Krishnamurthy S. Repeated olanzapine treatmentmitigates PTSD like symptoms in rats with changes in cell signalingfactors. Brain Res Bull. 2018;140:365-77. doi: 10.1016/j.brainresbull.2018.06.003

  36. Boz Z, Hu M, Yu Y, Huang XF. N-acetylcysteine prevents olanzapineinducedoxidative stress in mHypoA-59 hypothalamic neurons.Sci Rep. 2020;10:19185. doi: 10.1038/s41598-020-75356-3

  37. Scalley RD, Conner CS. Acetaminophen poisoning: a case reportof the use of acetylcysteine. Am J Hosp Pharm. 1978;35(8):964-7.

  38. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M.N-acetylcysteine for antioxidant therapy: pharmacology andclinical utility. Expert Opin Biol Ther. 2008;8(12):1955-62. doi:10.1517/14728220802517901

  39. Rossell SL, Francis PS, Galletly C, Harris A, Siskind D, BerkM, et al. N -acetylcysteine (NAC) in schizophrenia resistant toclozapine: a double-blind randomised placebo controlled trialtargeting negative symptoms. BMC Psychiatry. 2016;16(1):1-9.doi: 10.1186/s12888-016-1030-3

  40. Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, etal. Clinical trials of N-acetylcysteine in psychiatry and neurology:A systematic review. Neurosci Biobehav Rev. 2015;55:294-321.doi: 10.1016/j.neubiorev.2015.04.015

  41. Kerksick C, Willoughby D. The antioxidant role of glutathioneand N-Acetyl-Cysteine supplements and exercise-inducedoxidative stress. J Int Soc Sports Nutr. 2005; 2(2):38. doi:10.1186/1550-2783-2-2-38

  42. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry:current therapeutic evidence and potential mechanisms ofaction. J Psychiatry Neurosci. 2011; 36(2):78-86. doi: 10.1503/jpn.100057

  43. Quintavalle C, Donnarumma E, Fiore D, Briguori C, CondorelliG. Therapeutic strategies to prevent contrast-induced acutekidney injury. Curr Opin Cardiol. 2013; 28(6):676-82. doi:10.1097/HCO.0b013e3283653f41

  44. Ng W, Kennar R, Uetrecht J. Effect of clozapine and olanzapineon neutrophil kinetics: Implications for drug-inducedagranulocytosis. Chem Res Toxicol. 2014;27(7):1104-8. doi:10.1021/tx500183x

  45. Triggs WJ, Willmore LJ. In vivo lipid peroxidation in rat brain followingintracortical Fe2+ injection. J Neurochem. 1984;42(4):976-80. doi: 10.1111/j.1471-4159.1984.tb12699.x

  46. Diaz-Ruiz A, Rios C, Duarte I, Correa D, Guizar-Sahagun G, Grijalva I, et al. Cyclosporin-A inhibits lipid peroxidation after spinal cordinjury in rats. Neurosci Lett. 1999;266(1):61-4. doi: 10.1016/s0304-3940(99)00255-4

  47. Diaz-Ruiz A, Alcaraz-Zubeldia M, Maldonado V, Salgado-Ceballos H, Mendez-Armenta M, Rios C. Differential time-course of theincrease of antioxidant thiol-defenses in the acute phase after spinal cord injury in rats. Neurosci Lett. 2009;452(1):56-9. doi: 10.1016/j.neulet.2009.01.020

  48. Wąsik A, Białoń M, Jantas D, Żarnowska M. The impact of the combined administration of 1MeTIQ and MK-801 on cell viability, oxidativestress markers, and glutamate release in the rat hippocampus. Neurotox Res. 2021;39(6):1747-61. doi: 10.1007/s12640-021-00428-9

  49. Ozyurt B, Ozyurt H, Akpolat N, Erdogan H, Sarsilmaz M. Oxidative stress in prefrontal cortex of rat exposed to MK-801 and protectiveeffects of CAPE. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):832-8. doi: 10.1016/j.pnpbp.2007.01.029

  50. Turkmen R, Akosman MS, Demirel HH. Protective effect of N-acetylcysteine on MK-801-induced testicular oxidative stress in mice. BiomedPharmacother. 2019;109:1988-93. doi: 10.1016/j.biopha.2018.09.139

  51. Smaga I, Pomierny B, Krzyżanowska W, Pomierny-Chamioło L, Miszkiel J, Niedzielska E, et al. N-acetylcysteine possesses antidepressantlikeactivity through reduction of oxidative stress: Behavioral and biochemical analyses in rats. Prog Neuropsychopharmacol Biol Psychiatry.2012;39(2):280-7. doi: 10.1016/j.pnpbp.2012.06.018

  52. Nucifora LG, Tanaka T, Hayes LN, Kim M, Lee BJ, Matsuda T, et al. Reduction of plasma glutathione in psychosis associated withschizophrenia and bipolar disorder in translational psychiatry. Transl Psychiatry. 2017;7(8):e1215. doi: 10.1038/tp.2017.178

  53. Do KQ, Trabesinger AH, Kirsten‐Krüger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid andprefrontal cortex in vivo. Eur J Neurosci. 2000;12(10):3721-8. doi: 10.1046/j.1460-9568.2000.00229.x

  54. Dean OM, Mancuso SG, Bush AI, Copolov D, Do KQ, Cuénod M, et al. Benefits of adjunctive N-acetylcysteine in a sub-group ofclozapine-treated individuals diagnosed with schizophrenia. Psychiatry Res. 2015;230(3):982-3 doi: 10.1016/j.psychres.2015.10.037




2020     |     www.medigraphic.com